These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 24171832)

  • 1. Local and systemic complications after intravitreal administration of anti-vascular endothelial growth factor agents in the treatment of different ocular diseases: a five-year retrospective study.
    Nuzzi R; Tridico F
    Semin Ophthalmol; 2015 Mar; 30(2):129-35. PubMed ID: 24171832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections.
    Frenkel MP; Haji SA; Frenkel RE
    Arch Ophthalmol; 2010 Dec; 128(12):1523-7. PubMed ID: 21149773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib.
    Choi DY; Ortube MC; McCannel CA; Sarraf D; Hubschman JP; McCannel TA; Gorin MB
    Retina; 2011 Jun; 31(6):1028-35. PubMed ID: 21836409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections.
    Hoang QV; Mendonca LS; Della Torre KE; Jung JJ; Tsuang AJ; Freund KB
    Ophthalmology; 2012 Feb; 119(2):321-6. PubMed ID: 22054994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents.
    Kim JE; Mantravadi AV; Hur EY; Covert DJ
    Am J Ophthalmol; 2008 Dec; 146(6):930-4.e1. PubMed ID: 18775528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration.
    Day S; Acquah K; Mruthyunjaya P; Grossman DS; Lee PP; Sloan FA
    Am J Ophthalmol; 2011 Aug; 152(2):266-72. PubMed ID: 21664593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Complications of intravitreal injections--own experience].
    Jamrozy-Witkowska A; Kowalska K; Jankowska-Lech I; Terelak-Borys B; Nowosielska A; Grabska-Liberek I
    Klin Oczna; 2011; 113(4-6):127-31. PubMed ID: 21913440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy.
    Hoang QV; Tsuang AJ; Gelman R; Mendonca LS; Della Torre KE; Jung JJ; Freund KB
    Retina; 2013 Jan; 33(1):179-87. PubMed ID: 22990314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents.
    Good TJ; Kimura AE; Mandava N; Kahook MY
    Br J Ophthalmol; 2011 Aug; 95(8):1111-4. PubMed ID: 20702430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections.
    van der Reis MI; La Heij EC; De Jong-Hesse Y; Ringens PJ; Hendrikse F; Schouten JS
    Retina; 2011 Sep; 31(8):1449-69. PubMed ID: 21817960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rate of serious adverse effects in a series of bevacizumab and ranibizumab injections.
    Sharma S; Johnson D; Abouammoh M; Hollands S; Brissette A
    Can J Ophthalmol; 2012 Jun; 47(3):275-9. PubMed ID: 22687306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retinal nerve fiber layer thickness in patients receiving chronic anti-vascular endothelial growth factor therapy.
    Horsley MB; Mandava N; Maycotte MA; Kahook MY
    Am J Ophthalmol; 2010 Oct; 150(4):558-561.e1. PubMed ID: 20643396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
    Sankar MJ; Sankar J; Chandra P
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD009734. PubMed ID: 29308602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The early effects of intravitreal anti vascular endothelial growth factor agents on intraocular pressure and central corneal thickness.
    Omay E; Elgin U; Sen E; Yilmazbas P
    Int Ophthalmol; 2016 Oct; 36(5):665-70. PubMed ID: 26780098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
    Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
    Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.
    Zehetner C; Kirchmair R; Huber S; Kralinger MT; Kieselbach GF
    Br J Ophthalmol; 2013 Apr; 97(4):454-9. PubMed ID: 23385630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting.
    Pilli S; Kotsolis A; Spaide RF; Slakter J; Freund KB; Sorenson J; Klancnik J; Cooney M
    Am J Ophthalmol; 2008 May; 145(5):879-82. PubMed ID: 18329624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease.
    Tolentino M
    Surv Ophthalmol; 2011; 56(2):95-113. PubMed ID: 21335144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and complications of intravitreal injections performed in an Asian population in Singapore.
    Xu Y; Tan CS
    Int Ophthalmol; 2017 Apr; 37(2):325-332. PubMed ID: 27236451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicity testing of the VEGF inhibitors bevacizumab, ranibizumab and pegaptanib in rats both with and without prior retinal ganglion cell damage.
    Thaler S; Fiedorowicz M; Choragiewicz TJ; Bolz S; Tura A; Henke-Fahle S; Yoeruek E; Zrenner E; Bartz-Schmidt KU; Ziemssen F; Schuettauf F
    Acta Ophthalmol; 2010 Aug; 88(5):e170-6. PubMed ID: 20491691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.